Barrios Evan L, Balzano-Nogueira Leandro, Polcz Valerie E, Rodhouse Christine, Leary Jack R, Darden Dijoia B, Rincon Jaimar C, Dirain Marvin L, Ungaro Ricardo, Nacionales Dina C, Larson Shawn D, Sharma Ashish, Upchurch Gilburt, Wallet Shannon M, Brusko Todd M, Loftus Tyler J, Mohr Alicia M, Maile Robert, Bacher Rhonda, Cai Guoshuai, Kladde Michael P, Mathews Clayton E, Moldawer Lyle L, Brusko Maigan A, Efron Philip A
Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, United States.
Diabetes Institute, University of Florida, Gainesville, FL, United States.
Front Immunol. 2024 Dec 3;15:1478471. doi: 10.3389/fimmu.2024.1478471. eCollection 2024.
Despite continued improvement in post-sepsis survival, long term morbidity and mortality remain high. Chronic critical illness (CCI), defined as persistent inflammation and organ injury requiring prolonged intensive care, is a harbinger of poor long-term outcomes in sepsis survivors. Current dogma states that sepsis survivors are immunosuppressed, particularly in CCI. Investigation of this immune suppression in heterogeneous immune populations across distinct clinical trajectories and outcomes, along with limited sampling access, is accessible via single-cell RNA sequencing (scRNA-seq).
scRNA-seq analysis was performed on healthy subjects (n=12), acutely septic patients at day 4 ± 1 (n=4), and those defined as rapid recovery (n=4) or CCI (n=5) at day 14-21. Differential gene expression and pathway analyses were performed on peripheral blood lymphocytes at both a population and annotated cell subset level. Cellular function was assessed via enzyme-linked immunosorbent spot (ELISpot), cytokine production analysis, and T-cell proliferation assays on an additional cohort of septic patients (19 healthy, 68 acutely septic, 27 rapid recovery and 20 classified as CCI 14-21 days after sepsis onset).
Sepsis survivors that developed CCI exhibited proportional shifts within lymphoid cell populations, with expanded frequency of CD8 and NK cells. Differential expression and pathway analyses revealed continued activation in T cells and NK cells, with generalized suppression of B-cell function. Both T and NK cell subsets displayed transcriptomic profiles of exhaustion and immunosuppression in CCI, particularly in CD8 T effector memory (TEM) cells and NK cells. Functional validation of T-cell behavior in an independent cohort demonstrated T cells maintained proliferative responses yet exhibited a marked loss of cytokine production. IFN-γ production at the acute phase (day 4 ± 1) was significantly reduced in subjects later classified as CCI.
Sepsis patients exhibit unique T-, B-, and NK-cell transcriptional patterns that are both time- and clinical trajectory-dependent. These transcriptomic and pathway differences in sepsis patients that develop CCI are associated with exhaustion in CD8 TEM cells and NK cells. Understanding the specific immune system patterns of different cell subsets after sepsis at a molecular level will be key to the development of personalized immunotherapy and drug-targeting intervention.
https://clinicaltrials.gov/, identifier NCT02276417.
尽管脓毒症后生存率持续提高,但长期发病率和死亡率仍然很高。慢性危重病(CCI)定义为需要长期重症监护的持续性炎症和器官损伤,是脓毒症幸存者长期预后不良的先兆。目前的观点认为脓毒症幸存者存在免疫抑制,尤其是在CCI患者中。通过单细胞RNA测序(scRNA-seq)可以在不同临床轨迹和结果的异质免疫群体中研究这种免疫抑制,同时该技术也解决了样本获取受限的问题。
对健康受试者(n = 12)、第4±1天的急性脓毒症患者(n = 4)以及在第14 - 21天被定义为快速康复(n = 4)或CCI(n = 5)的患者进行scRNA-seq分析。在群体和注释细胞亚群水平上对外周血淋巴细胞进行差异基因表达和通路分析。通过酶联免疫斑点法(ELISpot)、细胞因子产生分析以及对另一组脓毒症患者(19名健康者、68名急性脓毒症患者、27名快速康复者和20名在脓毒症发作后14 - 21天被归类为CCI的患者)进行T细胞增殖试验来评估细胞功能。
发展为CCI的脓毒症幸存者在淋巴细胞群体中表现出比例变化,CD8和NK细胞频率增加。差异表达和通路分析显示T细胞和NK细胞持续激活,B细胞功能普遍受到抑制。在CCI患者中,T细胞和NK细胞亚群均表现出耗竭和免疫抑制的转录组特征,尤其是在CD8 T效应记忆(TEM)细胞和NK细胞中。在一个独立队列中对T细胞行为进行功能验证表明,T细胞保持增殖反应,但细胞因子产生明显减少。在后期被归类为CCI的受试者中,急性期(第4±1天)的IFN-γ产生显著降低。
脓毒症患者表现出独特的T、B和NK细胞转录模式,这些模式既依赖时间也依赖临床轨迹。发展为CCI的脓毒症患者的这些转录组和通路差异与CD8 TEM细胞和NK细胞的耗竭有关。在分子水平上了解脓毒症后不同细胞亚群的特定免疫系统模式将是开发个性化免疫疗法和药物靶向干预的关键。